BPCR — Biopharma Credit Income Statement
0.000.00%
- $964.45m
- $958.83m
- $150.03m
- 80
- 81
- 74
- 95
Annual income statement for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 110 | 104 | 218 | 136 | 150 |
Cost of Revenue | |||||
Gross Profit | 91.4 | 88 | 184 | 110 | 124 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 20.9 | 18.9 | 35.8 | 27.3 | 27.9 |
Operating Profit | 89.1 | 85 | 182 | 108 | 122 |
Net Income Before Taxes | 89.1 | 85 | 182 | 108 | 122 |
Provision for Income Taxes | |||||
Net Income After Taxes | 89.1 | 85 | 182 | 108 | 122 |
Net Income Before Extraordinary Items | |||||
Net Income | 89.1 | 85 | 182 | 108 | 122 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 89.1 | 85 | 182 | 108 | 122 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.065 | 0.062 | 0.134 | 0.083 | 0.1 |
Dividends per Share | |||||
Special Dividends per Share |